Enhanced delivery of carboplatin into brain tumours with intravenous CereportTM (RMP-7): dramatic differences and insight gained from dosing parameters
1999
Improving Carboplatin Delivery to Brain Tumors with Cereport
publication
Evidence: moderate
Author Information
Author(s): Emerich D F, Snodgrass P, Dean R, Agostino M, Hasler B, Pink M, Xiong H, Kim B S, Bartus R T
Primary Institution: Alkermes Inc.
Hypothesis
Can Cereport enhance the delivery of carboplatin into brain tumors by increasing the permeability of the blood-brain tumor barrier?
Conclusion
The study found that adjusting the timing of carboplatin and Cereport infusions significantly improved the delivery of carboplatin to brain tumors.
Supporting Evidence
- Cereport increases the permeability of the blood-brain tumor barrier.
- Carboplatin levels were doubled when given as a bolus during the Cereport infusion.
- Co-infusion of Cereport and carboplatin did not increase carboplatin levels due to tachyphylaxis.
- Timing adjustments of the infusions led to significant uptake effects.
Takeaway
This study shows that using a special drug called Cereport can help get more chemotherapy into brain tumors if given at the right time.
Methodology
Experiments were conducted in an RG2 rodent model of glioma to evaluate intravenous parameters for optimizing Cereport's clinical use.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website